HudakJMBanitEHSchmidJR. Discovery and development of flecainide. Am J Cardiol1984; 53 (5): 17–20B.
2.
EstesNAGaranHRuskinJN. Electrophysiologic properties of flecainide acetate. Am J Cardiol1985; 53 (5): 26–9B.
3.
HellestrandKJNathanAWBextonRSCammAJ. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections and pacemaker thresholds. Am J Cardiol1984; 53 (5): 30–8B.
4.
MilneJRHellestrandKJBextonRSBurnettPJDebbasNMCammAJ. Class I antiarrhythmic drugs—characteristic electrocardiographic differences when assessed by atrial and ventricular pacing. Eur Heart J1984; 2: 99–107.
5.
LegrandVVandormaelMCollignonPKulbertusHE. Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease. Am J Cardiol1983; 51: 422–6.
6.
ConardGJOberRE. Metabolism of flecainide. Am J Cardiol1984; 53 (5): 41–51B.
7.
CaplinJLJohnstonACammAJ. Changes in “in vitro” serum protein binding of disopyramide and flecainide after acute myocardial infarction (abstract). Br Heart J1983; 49: 298.
8.
FranciosaJAWilenMWeeksCETanenbaumRKvamDCMillerAM. Pharmacokinetics and hemodynamic effect of flecainide in patients with chronic low output heart failure (abstract). J Am Coll Cardiol1983; 1: 699.
9.
ConradGJCarlsonGLFrostJWOberRE. Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans. Clin Ther1984; 6: 643–52.
10.
HodgesMHauglandJMGrandrudG. Suppression of ventricular ectopic depolarizations by flecainide acetate, new antiarrhythmic agent. Circulation1982; 65: 879–85.
11.
AndersonJLStewartJRPennyBA. Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med1981; 305: 473–7.
12.
DuffHJRodenDMMattucciRJ. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol1981; 48: 1133–40.
13.
AbitbolHCalifanoJEAbateCBeilisPCastellanosH. Use of flecainide acetate in the treatment of premature ventricular contractions. Am Heart J1983; 105: 227–30.
14.
StroobandtRAndriesEVan MieghemWKestelootH. Efficacy and tolerance of intravenous flecainide in patients with chronic high frequency ventricular arrhythmias. Eur Heart J1984; 5: 876–82.
15.
VanhaleweykGBalakumaranKLubsenFJ. Flecainide: One-year efficacy in patients with chronic ventricular arrhythmias. Eur Heart J1984; 5: 814–23.
16.
AndersonJLLutzJRAllisonSB. Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. J Am Coll Cardiol1983; 2: 105–14.
17.
FlowersDO'GallagherRNTorresVMiuraDSombergJC. Flecainide: Long-term treatment using a reduced dosing schedule. Am J Cardiol1985; 55: 79–83.
18.
DuranDPlatiaEVGriffithLSCAdharGReidPR. Suppression of complex ventricular arrhythmias by oral flecainide. Clin Pharmacol Ther1982; 32: 554–61.
19.
AndersonJLStewartJRPerryBA. Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med1981; 305: 473–7.
20.
DuffJHRodenDMMaffucciRJ. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol1981; 48: 1133–40.
21.
DuranDPlatiaEVGriffithLSCAdharGReidPR. Suppression of complex ventricular arrhythmias by oral flecainide. Clin Pharmacol Ther1982; 32: 554–61.
22.
HodgesMHaughlandMJGranrudGConardGJAsingerRWMidellFL. Suppression of ventricular ectopic depolarizations by flecainide acetate: A new antiarrhythmic agent. Circulation1982; 65: 879–85.
23.
KjekshusJBathenJOrningOMStorsteinL. A double-blind crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol1984; 53 (5): 72–8B.
24.
HodgesMSalernoDMGranrudG. Flecainide versus quinidine: Results of a multicenter trial. Am J Cardiol1984; 53 (5): 66–71B.
25.
HolmesBHeelRC. Flecainide: A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs1985; 29: 1–33.
26.
HellestrandKJNathanAWBextonRSRoworthASpurrellJCammAJ. Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. Am J Cardiol1983; 51: 770–6.
27.
SomaniP. Antiarrhythmic effects of flecainide. Clin Pharmacol Ther1980; 27: 464–70.
28.
HellestrandKJNathanAWBextonRSCammAJ. The electrophysiological effects of flecainide acetate on sinus node function, anomalous A-V connections, and pacemaker thresholds. Am J Cardiol1984; 53: 30–8B.
29.
BextonRSHellestrandKJNathanAW. A comparison of the antiarrhythmic effects on AV junctional re-entrant tachycardia of oral and intravenous flecainide acetate. Eur Heart J1983; 4: 92–102.
30.
KappenbergerLShenasaMFromerMSteinbrunnW. Evaluation of flecainide in atrial fibrillation complicating Wolff-Parkinson-White syndrome. Eur Heart J1984; 5 (B): 123.
31.
NeussHBussJSchlepperM. Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. Eur Heart J1983; 4: 347–53.
32.
GentzkowGDSullivanJY. Extracardiac adverse effects of flecainide. Am J Cardiol1984; 53 (5): 101–5B.
33.
Data on file. Investigator's brochure, R-818 (flecainide acetate, Tambocor), oral and parenteral antiarrhythmic, July 1983. Riker Laboratories, Inc.; St. Paul, MN.
34.
MorganrothJHorowitzLN. Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol1984; 53: 89–94B.
35.
EstesNAMIIIGaranHRuskinJN. Electrophysiologic properties of flecainide acetate. Am J Cardiol1984; 53: 26–9B.
36.
LuiHKLeeGDietrichP. Flecainide-induced QT prolongation and ventricular tachycardia. Am Heart J1982; 103: 567–9.
37.
LewisGPHoltzmanJL. Interaction of flecainide with digoxin and propranolol. Am J Cardiol1984; 53: 52–7B.
